On 12 January 2026, the UK's MHRA approved a new high-dose 7.2 mg injection of Wego (semaglutide) for the treatment of obesity in adults.[1] This dose is intended for patients who have not achieved sufficient weight loss on the lower dose of 2.4 mg.[1] The approval follows data from the STEP UP trial, which showed that patients on the 7.2 mg dose lost an average of 18.7% of their body weight compared to 3.9% in the placebo group.[1] After 72 weeks of treatment with adherence to the regimen, patients lost 20.7% of their weight compared to 2.4% in the placebo group.[1] A third of patients taking the 7.2 mg dose lost 25% or more of their body weight.[1] The study also demonstrated that the higher dose has a similar safety profile to the lower dose of 2.4 mg.[1] Around 15 million people in the UK are obese and it is predicted that by 2040, 71% of British adults will be obese or overweight.[1] A single injection with a dose of 7.2 mg should be available during 2026.[1]